Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2011 1
2014 3
2015 5
2016 3
2017 3
2018 5
2019 5
2020 13
2021 3
2022 8
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean xiangyang li (508 results)?
Targeting CD39 in cancer.
Moesta AK, Li XY, Smyth MJ. Moesta AK, et al. Nat Rev Immunol. 2020 Dec;20(12):739-755. doi: 10.1038/s41577-020-0376-4. Epub 2020 Jul 29. Nat Rev Immunol. 2020. PMID: 32728220 Review.
NMDAR antagonists suppress tumor progression by regulating tumor-associated macrophages.
Yuan D, Hu J, Ju X, Putz EM, Zheng S, Koda S, Sun G, Deng X, Xu Z, Nie W, Zhao Y, Li X, Dougall WC, Shao S, Chen Y, Tang R, Zheng K, Yan J. Yuan D, et al. Among authors: li x. Proc Natl Acad Sci U S A. 2023 Nov 21;120(47):e2302126120. doi: 10.1073/pnas.2302126120. Epub 2023 Nov 15. Proc Natl Acad Sci U S A. 2023. PMID: 37967215
CD155 in tumor progression and targeted therapy.
Zhan M, Zhang Z, Zhao X, Zhang Y, Liu T, Lu L, Li XY. Zhan M, et al. Cancer Lett. 2022 Oct 1;545:215830. doi: 10.1016/j.canlet.2022.215830. Epub 2022 Jul 20. Cancer Lett. 2022. PMID: 35870689 Review.
Review immune response of targeting CD39 in cancer.
Liu Y, Li Z, Zhao X, Xiao J, Bi J, Li XY, Chen G, Lu L. Liu Y, et al. Biomark Res. 2023 Jun 7;11(1):63. doi: 10.1186/s40364-023-00500-w. Biomark Res. 2023. PMID: 37287049 Free PMC article. Review.
NKG7 Is Required for Optimal Antitumor T-cell Immunity.
Li XY, Corvino D, Nowlan B, Aguilera AR, Ng SS, Braun M, Cillo AR, Bald T, Smyth MJ, Engwerda CR. Li XY, et al. Cancer Immunol Res. 2022 Feb;10(2):154-161. doi: 10.1158/2326-6066.CIR-20-0649. Epub 2022 Jan 10. Cancer Immunol Res. 2022. PMID: 35013002
Tumor intrinsic and extrinsic immune functions of CD155.
O'Donnell JS, Madore J, Li XY, Smyth MJ. O'Donnell JS, et al. Semin Cancer Biol. 2020 Oct;65:189-196. doi: 10.1016/j.semcancer.2019.11.013. Epub 2019 Dec 26. Semin Cancer Biol. 2020. PMID: 31883911 Review.
CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.
Li XY, Das I, Lepletier A, Addala V, Bald T, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, Braun M, Nakamura K, Jacquelin S, Lane SW, Teng MW, Dougall WC, Smyth MJ. Li XY, et al. J Clin Invest. 2022 Mar 15;132(6):e159825. doi: 10.1172/JCI159825. J Clin Invest. 2022. PMID: 35289314 Free PMC article. No abstract available.
The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation.
Ng SS, De Labastida Rivera F, Yan J, Corvino D, Das I, Zhang P, Kuns R, Chauhan SB, Hou J, Li XY, Frame TCM, McEnroe BA, Moore E, Na J, Engel JA, Soon MSF, Singh B, Kueh AJ, Herold MJ, Montes de Oca M, Singh SS, Bunn PT, Aguilera AR, Casey M, Braun M, Ghazanfari N, Wani S, Wang Y, Amante FH, Edwards CL, Haque A, Dougall WC, Singh OP, Baxter AG, Teng MWL, Loukas A, Daly NL, Cloonan N, Degli-Esposti MA, Uzonna J, Heath WR, Bald T, Tey SK, Nakamura K, Hill GR, Kumar R, Sundar S, Smyth MJ, Engwerda CR. Ng SS, et al. Nat Immunol. 2020 Oct;21(10):1205-1218. doi: 10.1038/s41590-020-0758-6. Epub 2020 Aug 24. Nat Immunol. 2020. PMID: 32839608 Free PMC article.
Tumor suppressor activity of RIG-I.
Li XY, Guo HZ, Zhu J. Li XY, et al. Mol Cell Oncol. 2014 Dec 31;1(4):e968016. doi: 10.4161/23723548.2014.968016. eCollection 2014 Oct-Dec. Mol Cell Oncol. 2014. PMID: 27308362 Free PMC article. Review.
55 results